Journal Article
. 2017 Apr; 164(2):461-466.
doi: 10.1007/s10549-017-4262-0.

A breast cancer gene signature for indolent disease

Leonie J M J Delahaye 1 Caroline A Drukker 2 Christa Dreezen 1 Anke Witteveen 1 Bob Chan 3 Mireille Snel 1 Inès J Beumer 1 Rene Bernards 1 M William Audeh 3 Laura J Van't Veer 4 Annuska M Glas 5 
  • PMID: 28451965
  •     14 References
  •     8 citations


Purpose: Early-stage hormone-receptor positive breast cancer is treated with endocrine therapy and the recommended duration of these treatments has increased over time. While endocrine therapy is considered less of a burden to patients compared to chemotherapy, long-term adherence may be low due to potential adverse side effects as well as compliance fatigue. It is of high clinical utility to identify subgroups of breast cancer patients who may have excellent long-term survival without or with limited duration of endocrine therapy to aid in personalizing endocrine treatment.

Methods: We describe a new ultralow risk threshold for the 70-gene signature (MammaPrint) that identifies a group of breast cancer patients with excellent 20 year, long-term survival prognosis. Tumors of these patients are referred to as "indolent breast cancer." We used patient series on which we previously established and assessed the 70-gene signature high-low risk threshold.

Results: In an independent validation cohort, we show that patients with indolent breast cancer had 100% breast cancer-specific survival at 15 years of follow-up.

Conclusions: Our data indicate that patients with indolent disease may be candidates for limited treatment with adjuvant endocrine therapy based on their very low risk of distant recurrences or death of breast cancer.

Keywords: Breast cancer; Indolent disease; MammaPrint; Ultralow threshold.

Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
REporting recommendations for tumor MARKer prognostic studies (REMARK).
Lisa M McShane, Douglas G Altman, +4 authors, Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics.
Breast Cancer Res Treat, 2006 Aug 26; 100(2). PMID: 16932852
Highly Cited.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas, Arno Floore, +9 authors, Laura J Van't Veer.
BMC Genomics, 2006 Nov 01; 7. PMID: 17074082    Free PMC article.
Highly Cited.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Jolien M Bueno-de-Mesquita, Wim H van Harten, +19 authors, Sabine C Linn.
Lancet Oncol, 2007 Nov 29; 8(12). PMID: 18042430
Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
Laura J Esserman, Yiwey Shieh, +8 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2011 Sep 06; 130(3). PMID: 21892702    Free PMC article.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
C A Drukker, J M Bueno-de-Mesquita, +10 authors, S C Linn.
Int J Cancer, 2013 Feb 02; 133(4). PMID: 23371464    Free PMC article.
Long-term impact of the 70-gene signature on breast cancer outcome.
C A Drukker, H van Tinteren, +4 authors, L J Van't Veer.
Breast Cancer Res Treat, 2014 Jan 22; 143(3). PMID: 24445566    Free PMC article.
Mammographic screening detects low-risk tumor biology breast cancers.
C A Drukker, M K Schmidt, +8 authors, L J Van't Veer.
Breast Cancer Res Treat, 2014 Jan 29; 144(1). PMID: 24469641    Free PMC article.
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
A S Coates, E P Winer, +6 authors, Panel Members.
Ann Oncol, 2015 May 06; 26(8). PMID: 25939896    Free PMC article.
Highly Cited.
Equivalence of MammaPrint array types in clinical trials and diagnostics.
Inès Beumer, Anke Witteveen, +11 authors, Annuska Glas.
Breast Cancer Res Treat, 2016 Mar 24; 156(2). PMID: 27002507    Free PMC article.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature.
Leonie Jm Delahaye, Diederik Wehkamp, +3 authors, Annuska M Glas.
Per Med, 2013 Nov 01; 10(8). PMID: 29776281
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Laura J Esserman, Christina Yau, +9 authors, Linda S Lindström.
JAMA Oncol, 2017 Jul 01; 3(11). PMID: 28662222    Free PMC article.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
Laura J van 't Veer, Christina Yau, +6 authors, Linda Sofie Lindström.
Breast Cancer Res Treat, 2017 Aug 05; 166(2). PMID: 28776283    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas.
Su-Min Ha, Shin Hwang, +10 authors, Sung-Gyu Lee.
Ann Surg Treat Res, 2018 Dec 07; 95(6). PMID: 30505821    Free PMC article.
Time intervals experienced between first symptom recognition and pathologic diagnosis of breast cancer in Addis Ababa, Ethiopia: a cross-sectional study.
Alem Gebremariam, Adamu Addissie, +4 authors, Ahmedin Jemal.
BMJ Open, 2019 Nov 14; 9(11). PMID: 31719089    Free PMC article.
RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery.
Nathan D Pennock, Sonali Jindal, +10 authors, Zheng Xia.
BMC Med Genomics, 2019 Dec 21; 12(1). PMID: 31856832    Free PMC article.
Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Gi Won Shin, Yang Zhang, +5 authors, Vivian Youngjean Park.
J Magn Reson Imaging, 2018 May 08; 48(6). PMID: 29734483    Free PMC article.
Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.
J M N Lopes Cardozo, M K Schmidt, +4 authors, C A Drukker.
Breast Cancer Res Treat, 2021 Jul 01;. PMID: 34191200